Description: What is the issuance of a COVID vaccine license? | Coronavirus News Plague

Since the United States last month supported a temporary suspension of the safety of the COVID-19 vaccine, the campaign to promote the production and production of ammunition has grown exponentially.

The United Nations has warned that international immunization coverage has contributed to the ongoing expansion of COVID-19 and increased the likelihood of a number of vaccines being developed.

World leaders have taken steps to combat the scourge of HIV / AIDS.

Last October, India and South Africa submitted a motion to the World Trade Organization (WTO) to temporarily suspend regulations on COVID-19 vaccine and other coronavirus-related drugs, saying the revocation of patents would allow many countries to make more important requirements. COVID-19.

Major medical companies and countries including the United Kingdom, Canada and Germany have opposed the plan, saying it could lead to disruptions and a lack of manufacturing facilities needed to expand operations.

More than 3 billion COVID-19 vaccines have been distributed worldwide according to Our Earth. But most of these drugs have been given in rich countries. At least two thirds of the drug is delivered in Africa.

“It’s very difficult,” said Yuanqiong Hu, a legal adviser at the Access Campaign for Doctors Without Border.

“We are seeing a lot of injustice in the world. They have a lot of ideas about who is the best and who makes them, ”he added.

At the fundraising talks to resume the WTO informal meeting on Wednesday, we will see a round of positive dialogue.

What is artistic freedom?

Intellectual Property (IP) rights varies from country to country. WTO interprets they as a right granted to human beings on the so-called “creatures”.

Developers can use IP rights to prevent others from using the content they have created or to negotiate subscriptions in exchange for a user license. Creatures can include designs, art, ideas or techniques, among others.

They are covered by legitimacy, identity and identity, which gives creators limited freedom of thought, while others are not allowed to copy. Biotech companies say this protects them from being made and manufactured COVID vaccine at the time of writing.

The WTO Convention on Intellectual Property Rights (TRIPS) “is a global IP agreement” and has been in place since 1995.

What does IP removal do?

The retaliator “temporarily removes” the reasonable protection afforded by the WTO.

The program of a request made by India and South Africa wants countries not to choose to use patents and other IP-related products and technologies, including diagnostics, drugs, vaccines, equipment and other materials or materials, as well as “their methods of preventing, treating or acquiring COVID -19”.

This could give countries the opportunity to increase cooperation in research and development, freeing WTO members from the risk of being exploited by others for not implementing the TRIPS Agreement during the epidemic.

It is possible for countries to use it wisely. The idea is for the donor to remain active for at least three years from the date of the election.

Duncan Matthews, director of the Queen Mary Intellectual Property Research Institute in London said, “The abolition of IP will not take away all commercial freedoms related to vaccinations, PPE, respirators and anything else.” “It gives opportunities to other countries to do this.”

“For example, we would not expect to see IP abolition in Europe, the US or other developed countries in the world. It would only provide an opportunity for middle- and low-income countries to offer such rights as they see fit to increase development and increase productivity,” he added.

Who opposes this work and why?

Organizations including the World Bank and the European Union, as well as countries including Japan, UK, Switzerland, Brazil and Australia have opposed this.

Some leaders have suggested that it could be a threat to innovation.

“I don’t think giving up patents is a way to make more people aware of the vaccine,” German Chancellor Angela Merkel told reporters in early May.

“I think we need the skills and expertise of the industry – and that’s why we need patent protection,” he added.

Some say that countries lack the resources, expertise and skills to develop vaccines. As an alternative, the EU has asked the US and the UK to increase exports of vaccines and end-of-life products.

“The European Union is the only continent or democracy in the world that sells exports,” Commission chief Ursula von der Leyen told a news conference in May.

“We call on all parties involved in the IP dispute to join us so that we can be prepared to export a large portion of what is being developed in the region,” he added.

Some say that even if the removal is removed, the potential for production it could not grow on its own in the short and medium term.

Pharmaceutical companies say they are negotiating a deal and Granting permits and prosecutors and prosecutors with the aim of protecting intellectual property and ensuring security.

Can discounts encourage production?

Manufacturers in Bangladesh, Canada, Denmark, and India have stated that they have the potential to develop vaccines, but are unable to do so due to a lack of licenses.

One example is Biolyse in Canada. The company manufactures cancer drugs and is believed to be one of the few companies in the country to develop the COVID-19 vaccine. but patent restrictions have failed from the front.

Human rights activists call on EU to end protests over COVID-19 removal [File: Evelyn Hockstein/Reuters]

However, in addition to the so-called “Secret” of the vaccine, manufacturers may also need to obtain trade secrets or information and expertise necessary in the development of the vaccine.

Professor Matthews said that this knowledge “is often in the human head. It’s a skill that you can use in the factory and know what to do if something goes wrong”.

“So how do you find these secrets? “The only way to do this is to send a specialist to train locals, because one of the things we have discussed here is not to have a country to do this on its own, it would be better to have a community,” he added.

The WTO does not have the power to force companies like Pfizer and Moderna, whose vaccines use RNA (mRNA) technology, to share this with other companies.

South Africa said so recently said received the first production of COVID-19 mRNA vaccine in Africa, with the support of WHO. The goal is enlargement production and acquisition of the COVID vaccine.

What’s next?

On June 30, the WTO TRIPS Council will hold its first meeting in a series of meetings scheduled for next month, with a discussion on the dynamics and clarification of the removal of TRIPS. The team should not start negotiations in writing, the most important thing in any competitive relationship.

“They have come up with an idea that addresses some of the challenges and advances the debate, the first meeting will be on what should be sold,” said Brook Baker, a professor at Northeastern University School of Law.

“They have tried to say that it is already a drug that inhibits, supports or regulates the spread of COVID-19, medical technologies and other substances, vaccines, drugs, diagnostic tests, PPE … so my question is which of these drugs’ Germany wants to include?

“Which ones have you never used? “What South Africa and India are asking for is the same thing that is available in rich countries,” he added.

Interviews with it is expected to continue, and an agreement to be made during the next WTO meeting to be held from November 30 to December 3.

“This work, even with the utmost urgency, even if all goes well, will not be completed until early December,” Matthews said.

Baker said there was concern that the lengthy negotiations would make the request less effective and that inviting pharma companies to negotiate could speed up the process.

“It’s just a threat that the removal should be enough to bring pharma to the table differently,” Baker explained.

“Wealthy countries can tell their drug companies that we need to increase their power … we can do this hard, which can take a long time, we will set up a discount … Or why not come to the table here, we will pay you, but you have to transfer your expertise, so we can make more, lower prices and equitable distribution around the world, ”he said.